Tags

Type your tag names separated by a space and hit enter

In vitro antimicrobial activity of narasin and monensin in combination with adjuvants against pathogens associated with canine otitis externa.
Vet Dermatol. 2020 Apr; 31(2):138-145.VD

Abstract

BACKGROUND

The emergence of antimicrobial resistance represents a serious human and animal health risk. Good antimicrobial stewardship is essential to prolong the lifespan of existing antibiotics, and new strategies are required to combat infections in man and animals.

HYPOTHESIS/OBJECTIVES

To determine the in vitro interaction of ionophores (narasin or monensin) with antimicrobial adjuvants (N-acetylcysteine (NAC), Tris-EDTA or disodium EDTA) against bacterial strains representing pathogens associated with canine otitis externa (OE).

ANIMAL/ISOLATES

American Type Culture Collection (ATCC) strains Staphylococcus aureus 29213, Pseudomonas aeruginosa 27853 and P. aeruginosa biofilm producer PAO1, and a clinical isolate of Proteus mirabilis from a case of canine OE were tested.

METHODS AND MATERIALS

A 2D microdilution checkerboard method was used, allowing calculation of fractional inhibitory concentration index (FICI), dose reduction index (DRI) and plotting of isobolograms.

RESULTS

The combination of narasin with either Tris-EDTA or disodium EDTA produced additive effects (FICI = 0.75) against P. aeruginosa ATCC 27853 and P. aeruginosa biofilm producer ATCC PAO1. An additive effect (FICI = 0.53-0.75) was found against S. aureus ATCC 29213 when narasin or monensin were combined with NAC. The highest DRI (32-fold) was found with monensin/NAC where the MIC of monensin was reduced from 4 to 0.125 μg/mL.

CONCLUSIONS AND CLINICAL IMPORTANCE

The combination of narasin with Tris-EDTA or disodium EDTA is a promising strategy to inhibit the intrinsic resistance elements of Gram-negative bacteria. These novel combinations potentially could be useful as a multimodal approach to treat mixed infections in canine OE.

Authors+Show Affiliations

Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy Campus, Mudla Wirra Rd, Roseworthy, South Australia, 5371, Australia. Faculty of Veterinary Medicine, Universiti Putra Malaysia, 43400 UPM, Serdang, Malaysia.Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy Campus, Mudla Wirra Rd, Roseworthy, South Australia, 5371, Australia.Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy Campus, Mudla Wirra Rd, Roseworthy, South Australia, 5371, Australia.Luoda Pharma Pty Ltd., 1/304-318, The Kingsway, Caringbah, New South Wales, 2229, Australia.Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy Campus, Mudla Wirra Rd, Roseworthy, South Australia, 5371, Australia.Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy Campus, Mudla Wirra Rd, Roseworthy, South Australia, 5371, Australia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31710159

Citation

Chan, Wei Yee, et al. "In Vitro Antimicrobial Activity of Narasin and Monensin in Combination With Adjuvants Against Pathogens Associated With Canine Otitis Externa." Veterinary Dermatology, vol. 31, no. 2, 2020, pp. 138-145.
Chan WY, Hickey EE, Khazandi M, et al. In vitro antimicrobial activity of narasin and monensin in combination with adjuvants against pathogens associated with canine otitis externa. Vet Dermatol. 2020;31(2):138-145.
Chan, W. Y., Hickey, E. E., Khazandi, M., Page, S. W., Trott, D. J., & Hill, P. B. (2020). In vitro antimicrobial activity of narasin and monensin in combination with adjuvants against pathogens associated with canine otitis externa. Veterinary Dermatology, 31(2), 138-145. https://doi.org/10.1111/vde.12803
Chan WY, et al. In Vitro Antimicrobial Activity of Narasin and Monensin in Combination With Adjuvants Against Pathogens Associated With Canine Otitis Externa. Vet Dermatol. 2020;31(2):138-145. PubMed PMID: 31710159.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro antimicrobial activity of narasin and monensin in combination with adjuvants against pathogens associated with canine otitis externa. AU - Chan,Wei Yee, AU - Hickey,Elizabeth E, AU - Khazandi,Manouchehr, AU - Page,Stephen W, AU - Trott,Darren J, AU - Hill,Peter B, Y1 - 2019/11/11/ PY - 2019/08/28/accepted PY - 2019/11/12/pubmed PY - 2019/11/12/medline PY - 2019/11/12/entrez SP - 138 EP - 145 JF - Veterinary dermatology JO - Vet Dermatol VL - 31 IS - 2 N2 - BACKGROUND: The emergence of antimicrobial resistance represents a serious human and animal health risk. Good antimicrobial stewardship is essential to prolong the lifespan of existing antibiotics, and new strategies are required to combat infections in man and animals. HYPOTHESIS/OBJECTIVES: To determine the in vitro interaction of ionophores (narasin or monensin) with antimicrobial adjuvants (N-acetylcysteine (NAC), Tris-EDTA or disodium EDTA) against bacterial strains representing pathogens associated with canine otitis externa (OE). ANIMAL/ISOLATES: American Type Culture Collection (ATCC) strains Staphylococcus aureus 29213, Pseudomonas aeruginosa 27853 and P. aeruginosa biofilm producer PAO1, and a clinical isolate of Proteus mirabilis from a case of canine OE were tested. METHODS AND MATERIALS: A 2D microdilution checkerboard method was used, allowing calculation of fractional inhibitory concentration index (FICI), dose reduction index (DRI) and plotting of isobolograms. RESULTS: The combination of narasin with either Tris-EDTA or disodium EDTA produced additive effects (FICI = 0.75) against P. aeruginosa ATCC 27853 and P. aeruginosa biofilm producer ATCC PAO1. An additive effect (FICI = 0.53-0.75) was found against S. aureus ATCC 29213 when narasin or monensin were combined with NAC. The highest DRI (32-fold) was found with monensin/NAC where the MIC of monensin was reduced from 4 to 0.125 μg/mL. CONCLUSIONS AND CLINICAL IMPORTANCE: The combination of narasin with Tris-EDTA or disodium EDTA is a promising strategy to inhibit the intrinsic resistance elements of Gram-negative bacteria. These novel combinations potentially could be useful as a multimodal approach to treat mixed infections in canine OE. SN - 1365-3164 UR - https://www.unboundmedicine.com/medline/citation/31710159/In_vitro_antimicrobial_activity_of_narasin_and_monensin_in_combination_with_adjuvants_against_pathogens_associated_with_canine_otitis_externa_ L2 - https://doi.org/10.1111/vde.12803 DB - PRIME DP - Unbound Medicine ER -